睿知中国医院研究地图
候选清单

北京北京大学医学部

北京大学肿瘤医院

Peking University Cancer Hospital

在本站收录的 53 种疾病中,这家医院列在其中 10 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

北京大学肿瘤医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma2 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma82 篇牵头论文牵头 6 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma42 篇牵头论文牵头 5 项开放试验
  4. 胃癌Stomach cancer223 篇牵头论文牵头 9 项开放试验
  5. 骨肉瘤Osteosarcoma4 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour12 篇牵头论文牵头 1 项开放试验
  7. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  8. 尤文肉瘤Ewing sarcoma2 篇牵头论文
  9. 多发性骨髓瘤Multiple myeloma3 篇牵头论文
  10. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis0 篇牵头论文

未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、脊索瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.08%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

北京有 6 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题放疗技术复发与转移
论文中的科室放疗科
牵头的论文2
  1. Distribution of regional lymph nodes metastasis in 870 cases of nasopharyngeal carcinoma and the suggestions for individualized elective prophylactic neck irradiation with intensity-modulated radiotherapy.2024Cancer medicine免费全文
  2. GLIM Criteria-Defined Malnutrition Informs on Survival of Nasopharyngeal Carcinoma Patients Undergoing Radiotherapy.2022Nutrition and cancer
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT05126719研究中心II期2023-04 启动
  2. PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma进行中,不再招募NCT04907370研究中心III期2021-08 启动
  3. A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma已完成NCT03866967研究中心II期2019-03 启动
  4. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)已完成NCT03924986研究中心III期2019-03 启动
  5. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  6. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma状态不明NCT02944708研究中心III期2015-10 启动
  7. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer状态不明NCT01074021研究中心III期2009-10 启动
PubMed 以外找到的论文(未计入)9
  1. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncology论文
  2. Impact of Radiotherapy on Radiation-Induced Brain Injury in Patients with Nasopharyngeal Carcinoma Using Nano-Magnetic Resonance Imaging2024Journal of Biomedical Nanotechnology论文
  3. 3D reconstruction-oriented fully automatic multi-modal tumor segmentation by dual attention-guided VNet2023The Visual Computer论文
  4. Clinical Evaluation of AI-Assisted Virtual Contrast Enhanced MRI in Primary Gross Tumor Volume Delineation for Radiotherapy of Nasopharyngeal Carcinoma2023Lecture notes in computer science会议论文
  5. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncology会议摘要
  6. Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.2022Journal of Clinical Oncology会议摘要
  7. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncology论文
  8. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要
  9. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 82 篇,占 2.8%。

牵头论文
82
2021–2025 年
牵头试验
30
任何状态,ClinicalTrials.gov
牵头的开放试验
6
正在或即将招募
作为研究中心的开放试验
11
由其他机构牵头
每年牵头的论文数
2021: 121220212022: 151520222023: 151520232024: 212120242025: 19192025

北京有 12 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 17

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
    分期
    II期
    开始
    2025-03
    登记号
    NCT06869213

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学肿瘤医院北京

  2. 正在招募
    QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2025-09
    登记号
    NCT07049185

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学肿瘤医院;另有 1 家列出的医院为研究中心北京

  3. 正在招募
    Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2024-11
    登记号
    NCT06684600

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学肿瘤医院北京

  4. 即将招募
    Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
    分期
    未注明
    开始
    2026-10
    登记号
    NCT07822906

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院北京

  5. 即将招募
    Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2022-12
    登记号
    NCT05386056

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院北京

  6. 邀请入组
    Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2025-11
    登记号
    NCT07312578

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:北京大学肿瘤医院北京

  7. 正在招募
    A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
    分期
    I/II期
    开始
    2026-03
    登记号
    NCT07405151

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、厦门、合肥、徐州、杭州、济南、郑州

  8. 正在招募
    QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    分期
    III期
    开始
    2026-04
    登记号
    NCT07463573

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  9. 正在招募
    A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
    分期
    II/III期
    开始
    2026-06
    登记号
    NCT07554456

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  10. 正在招募
    Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
    分期
    II期
    开始
    2026-07
    登记号
    NCT07733830

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院;另有 6 家列出的医院为研究中心北京、天津、太原、成都、沈阳、郑州

  11. 正在招募
    A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-09
    登记号
    NCT07751341

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、郑州

  12. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

  13. 正在招募
    Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
    分期
    I/II期
    开始
    2025-07
    登记号
    NCT06780111

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、厦门、合肥、徐州、郑州

  14. 正在招募
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    分期
    I期
    开始
    2024-07
    登记号
    NCT06465069

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京、广州

  15. 正在招募
    A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
    分期
    I/II期
    开始
    2023-05
    登记号
    NCT05319730

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、北京、厦门、合肥、新乡、杭州、郑州

  16. 正在招募
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    分期
    I期
    开始
    2022-10
    登记号
    NCT05208762

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京

  17. 即将招募
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    分期
    II期
    开始
    2026-06
    登记号
    NCT07623642

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、哈尔滨

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术新辅助与综合治疗分子标志物与基因
论文中的科室肿瘤内科影像/核医学科放疗科
牵头的论文82
  1. Extremely early genomic events and temporal order of esophageal squamous cell carcinogenesis: Longitudinal self-comparison of progressors and non-progressors.2025American journal of human genetics免费全文
  2. Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers.2025BMC cancer免费全文
  3. Expression of kinetochore component NDC80 promotes esophageal squamous cell carcinoma cells proliferation and migration.2025BMC gastroenterology免费全文
  4. Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers.2025Cancer biology & medicine免费全文
  5. Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions.2025Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  6. An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinoma.2025Cancer immunology, immunotherapy : CII免费全文
  7. PAF signaling axis functions as biomarker or target for esophageal squamous cell carcinoma diagnosis or treatment.2025Cancer letters
  8. Identification and characterization of Bufalin as a novel EGFR degrader.2025Cancer letters
  9. SQLE amplification accelerates esophageal squamous cell carcinoma tumorigenesis and metastasis through oncometabolite 2,3-oxidosqualene repressing Hippo pathway.2025Cancer letters
  10. An Image-Based Model for Assisting in Diagnosing Malignant Esophageal Lesions During Lugol Chromoendoscopic Examination.2025Clinical and translational gastroenterology免费全文
  11. Persistence of Lugol-unstaining Is Associated With an Increased Risk of Progression to Malignancy in the Esophagus.2025Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  12. Prognostic impact of recurrent laryngeal nerve lymph node metastatic status in thoracic esophageal squamous cell carcinoma.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  13. Integrating tumour and lymph node radiomics features for predicting disease-free survival in locally advanced esophageal squamous cell cancer after neoadjuvant chemotherapy and complete resection.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  14. NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.2025Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT免费全文
  15. Integrative analysis of T cell-mediated tumor killing-related genes reveals KIF11 as a novel therapeutic target in esophageal squamous cell carcinoma.2025Journal of translational medicine免费全文
  16. Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy.2025Nature communications免费全文
  17. A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial.2025Nature medicine免费全文
  18. Focal adhesion kinase/Src family kinase axis-mediated tyrosine phosphorylation of metabolic enzymes facilitates tumor metastasis.2025Signal transduction and targeted therapy免费全文
  19. Treatment choices after endoscopic resection for pMM/SM1 esophageal squamous cell cancer: a retrospective study in China.2025Surgical endoscopy免费全文
  20. METTL3-mediated upregulation of FAM135B promotes EMT of esophageal squamous cell carcinoma via regulating the Wnt/β-catenin pathway.2024American journal of physiology. Cell physiology
  21. Early Contrast-Enhanced MR for Diagnosing Complete Tumor Response of Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy: A Retrospective Comparative Study.2024Annals of surgical oncology
  22. ASO Author Reflections: The Challenging Journey from cCR to pCR After Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma.2024Annals of surgical oncology
  23. Long-Term Survival and Recurrence Patterns in Locally Advanced Esophageal Squamous Cell Carcinoma Patients with Pathologic Complete Response After Neoadjuvant Chemotherapy Followed by Surgery.2024Annals of surgical oncology
  24. Exploration of lymph node recurrence patterns and delineation guidelines of radiation field in middle thoracic oesophageal carcinomas after radical surgery: a real-world study.2024BMC cancer免费全文
  25. IGH repertoire analysis at scale: deciphering the complexity of B cell infiltration and migration in esophageal squamous cell carcinoma.2024Cancer gene therapy
  26. Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.2024Cancer immunology, immunotherapy : CII免费全文
  27. Somatic CDKN2A copy number variations are associated with the prognosis of esophageal squamous cell dysplasia.2024Chinese medical journal免费全文
  28. Tumor-associated macrophage (TAM)-secreted CCL22 confers cisplatin resistance of esophageal squamous cell carcinoma (ESCC) cells via regulating the activity of diacylglycerol kinase α (DGKα)/NOX4 axis.2024Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  29. LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma.2024Future oncology (London, England)免费全文
  30. Leveraging new methods for comprehensive characterization of mitochondrial DNA in esophageal squamous cell carcinoma.2024Genome medicine免费全文
  31. Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma.2024International immunopharmacology
  32. Surgical quality determines the long-term survival superiority of right over left thoracic esophagectomy for localized esophageal squamous cell carcinoma patients: a real-world multicenter study.2024International journal of surgery (London, England)免费全文
  33. Genome-Scale Multimodal Analysis of Cell-Free DNA Whole-Methylome Sequencing for Noninvasive Esophageal Cancer Detection.2024JCO precision oncology
  34. Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial.2024Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT
  35. Co-targeting TMEM16A with a novel monoclonal antibody and EGFR with Cetuximab inhibits the growth and metastasis of esophageal squamous cell carcinoma.2024Journal of translational medicine免费全文
  36. Community prevention and standardized clinical treatment jointly improve cancer outcome: Real-world evidence from an esophageal cancer patient cohort study.2024Science bulletin
  37. miR-378a-5p exerts tumor-suppressive effects on esophageal squamous cell carcinoma after neoadjuvant immunotherapy by downregulating APOC1/CEP55.2024Scientific reports免费全文
  38. Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma.2024Signal transduction and targeted therapy免费全文
  39. AKT2S128/CCTαS315/319/323-positive cancer-associated fibroblasts (CAFs) mediate focal adhesion kinase (FAK) inhibitors resistance via secreting phosphatidylcholines (PCs).2024Signal transduction and targeted therapy免费全文
  40. Exploration of the pattern of lymph node metastasis in esophageal cancer based on membrane anatomy theory.2024Thoracic cancer免费全文
  41. Long noncoding RNA LINC01088 inhibits esophageal squamous cell carcinoma progression by targeting the NPM1-HDM2-p53 axis.2023Acta biochimica et biophysica Sinica免费全文
  42. Minimally Invasive or Open Esophagectomy for Treatment of Resectable Esophageal Squamous Cell Carcinoma? Answer From a Real-world Multicenter Study.2023Annals of surgery
  43. Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-World Data.2023Annals of surgery
  44. CT radiomics features of meso-esophageal fat in predicting overall survival of patients with locally advanced esophageal squamous cell carcinoma treated by definitive chemoradiotherapy.2023BMC cancer免费全文
  45. A CT-Based Radiomics Nomogram Model for Differentiating Primary Malignant Melanoma of the Esophagus from Esophageal Squamous Cell Carcinoma.2023BioMed research international免费全文
  46. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma.2023Cancer cell
  47. Combined Wee1 and EGFR inhibition reveals synergistic antitumor effect in esophageal squamous cell carcinoma.2023Carcinogenesis
  48. Absence of Lugol staining indicates initiation of esophageal squamous cell carcinoma: A combined genomic and epidemiologic study.2023Cell reports. Medicine免费全文
  49. Quantitative CT evaluation after two cycles of induction chemotherapy to predict prognosis of patients with locally advanced oesophageal squamous cell carcinoma before undergoing definitive chemoradiotherapy/radiotherapy.2023European radiology免费全文
  50. High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial.2023International journal of radiation oncology, biology, physicsRCT
  51. Lugol-unstained lesions location in the esophagus affects the detection rate of malignancy: a population-based study.2023Journal of gastroenterology and hepatologyRCT
  52. Efficacy and Safety Profile of PD-1 Inhibitors Versus Chemotherapy in the Second-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2023Journal of immunotherapy (Hagerstown, Md. : 1997)
  53. Src heterodimerically activates Lyn or Fyn to serve as targets for the diagnosis and treatment of esophageal squamous cell carcinoma.2023Science China. Life sciences
  54. CDK7-YAP-LDHD axis promotes D-lactate elimination and ferroptosis defense to support cancer stem cell-like properties.2023Signal transduction and targeted therapy免费全文
  55. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.2023The Lancet. Oncology
  56. Primary malignant melanoma of the esophagus: differentiation from esophageal squamous cell carcinoma and leiomyoma using dynamic contrast-enhanced CT findings.2022Abdominal radiology (New York)免费全文
  57. Response to Comment on: "Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-world Data".2022Annals of surgery
  58. Combined Mean Corpuscular Hemoglobin, Fibrinogen, and Albumin (MF-A) Is a Novel Prognostic Marker in Patients with Resectable Esophageal Squamous Cell Carcinoma.2022Annals of surgical oncology
  59. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.2022BMJ (Clinical research ed.)RCT免费全文
  60. Tumor-associated macrophage (TAM)-derived CCL22 induces FAK addiction in esophageal squamous cell carcinoma (ESCC).2022Cellular & molecular immunology免费全文
  61. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.2022ESMO openRCT免费全文
  62. The m6A-induced lncRNA CASC8 promotes proliferation and chemoresistance via upregulation of hnRNPL in esophageal squamous cell carcinoma.2022International journal of biological sciences免费全文
  63. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.2022Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT免费全文
  64. Characterization of somatic structural variations in 528 Chinese individuals with Esophageal squamous cell carcinoma.2022Nature communications免费全文
  65. Postoperative lymphatic recurrence distribution and delineation of the radiation field in lower thoracic squamous cell esophageal carcinomas: a real-world study.2022Radiation oncology (London, England)免费全文
  66. Nuclear genome-derived circular RNA circPUM1 localizes in mitochondria and regulates oxidative phosphorylation in esophageal squamous cell carcinoma.2022Signal transduction and targeted therapy免费全文
  67. Absence of NOTCH1 mutation and presence of CDKN2A deletion predict progression of esophageal lesions.2022The Journal of pathology
  68. Commentary: Endoscopic treatment is the key for superficial esophageal squamous cell neoplasia.2022The Journal of thoracic and cardiovascular surgery
  69. Association between polymorphisms of ABCB1 and prognosis in esophageal squamous cell carcinoma patients treated with taxane.2022The journal of gene medicine
  70. The metabolic genomic atlas reveals potential drivers and clinically relevant insights into the etiology of esophageal squamous cell carcinoma.2022Theranostics免费全文
  71. MAGE-C3 promotes cancer metastasis by inducing epithelial-mesenchymal transition and immunosuppression in esophageal squamous cell carcinoma.2021Cancer communications (London, England)免费全文
  72. BAALC-AS1/G3BP2/c-Myc feedback loop promotes cell proliferation in esophageal squamous cell carcinoma.2021Cancer communications (London, England)免费全文
  73. Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities.2021Cancer medicine免费全文
  74. NOX5 mediates the crosstalk between tumor cells and cancer-associated fibroblasts via regulating cytokine network.2021Clinical and translational medicine免费全文
  75. Tumor-associated autoantibodies in ESCC screening: Detecting prevalent early-stage malignancy or predicting future cancer risk?2021EBioMedicine免费全文
  76. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.2021Future oncology (London, England)RCT
  77. Polymorphism of FGD4 and myelosuppression in patients with esophageal squamous cell carcinoma.2021Future oncology (London, England)
  78. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.2021JAMA surgeryRCT免费全文
  79. Genomic and epigenomic evolution of acquired resistance to combination therapy in esophageal squamous cell carcinoma.2021JCI insight免费全文
  80. Predicting Lymph Node Metastasis Using Computed Tomography Radiomics Analysis in Patients With Resectable Esophageal Squamous Cell Carcinoma.2021Journal of computer assisted tomography
  81. Feed-forward activation of STAT3 signaling limits the efficacy of c-Met inhibitors in esophageal squamous cell carcinoma (ESCC) treatment.2021Molecular carcinogenesis
  82. MXD1 is a Potential Prognostic Biomarker and Correlated With Specific Molecular Change and Tumor Microenvironment Feature in Esophageal Squamous Cell Carcinoma.2021Technology in cancer research & treatment免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)59
  1. Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery即将招募NCT07822906牵头方2026-10 启动
  2. A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma正在招募NCT06869213牵头方II期2025-03 启动
  3. QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma正在招募NCT07049185牵头方II期2025-09 启动
  4. Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer进行中,不再招募NCT07745322牵头方2026-05 启动
  5. HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma已完成NCT06184841牵头方I期2020-06 启动
  6. Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions状态不明NCT04170257牵头方不分期2019-10 启动
  7. Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma已完成NCT02850991牵头方不分期2016-04 启动
  8. Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma邀请入组NCT07312578牵头方(推断)II期2025-11 启动
  9. Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma正在招募NCT06684600牵头方(推断)II期2024-11 启动
  10. Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma即将招募NCT05386056牵头方(推断)II期2022-12 启动
  11. Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma状态不明NCT06690476牵头方(推断)早期I期2024-10 启动
  12. Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer状态不明NCT05866510牵头方(推断)II期2023-05 启动
  13. To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC状态不明NCT05818982牵头方(推断)II期2023-02 启动
  14. Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma已终止NCT04804696牵头方(推断)II期2021-02 启动
  15. JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy状态不明NCT05164848牵头方(推断)I期2021-12 启动
  16. The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma状态不明NCT04937673牵头方(推断)II期2021-07 启动
  17. Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification状态不明NCT04880811牵头方(推断)II期2021-07 启动
  18. Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics状态不明NCT04584008牵头方(推断)不分期2020-09 启动
  19. Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)状态不明NCT03833466牵头方(推断)II期2019-02 启动
  20. Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)状态不明NCT03940976牵头方(推断)II期2019-04 启动
  21. Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System状态不明NCT03185988牵头方(推断)II期2017-07 启动
  22. Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma已终止NCT03251417牵头方(推断)II期2017-09 启动
  23. Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT03126708牵头方(推断)II期2017-04 启动
  24. Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma已完成NCT02645864牵头方(推断)I期2016-01 启动
  25. Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer状态不明NCT02375997牵头方(推断)III期2014-10 启动
  26. Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma已撤回NCT02272699牵头方(推断)II/III期2014-11 启动
  27. Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.状态不明NCT01993784牵头方(推断)I/II期2013-08 启动
  28. Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer状态不明NCT02016287牵头方(推断)II期2013-12 启动
  29. Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer状态不明NCT02016274牵头方(推断)II期2013-12 启动
  30. Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)进行中,不再招募NCT01688908牵头方(推断)不分期2012-01 启动
  31. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC正在招募NCT07733830研究中心II期2026-07 启动
  32. QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma正在招募NCT07463573研究中心III期2026-04 启动
  33. A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.即将招募NCT07623642研究中心II期2026-06 启动
  34. A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma正在招募NCT07751341研究中心II期2026-09 启动
  35. A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)正在招募NCT07554456研究中心II/III期2026-06 启动
  36. A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)正在招募NCT07405151研究中心I/II期2026-03 启动
  37. Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)正在招募NCT06780111研究中心I/II期2025-07 启动
  38. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  39. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors正在招募NCT06465069研究中心I期2024-07 启动
  40. A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)正在招募NCT05319730研究中心I/II期2023-05 启动
  41. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors正在招募NCT05208762研究中心I期2022-10 启动
  42. A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)进行中,不再招募NCT06304974研究中心III期2024-03 启动
  43. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  44. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  45. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  46. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).已终止NCT04949256研究中心III期2021-07 启动
  47. JAB-3068 Activity in Adult Patients With Advanced Solid Tumors已完成NCT04721223研究中心I/II期2021-04 启动
  48. A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China已完成NCT04121286研究中心I期2020-07 启动
  49. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  50. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  51. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
  52. Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )已完成NCT03748134研究中心III期2018-12 启动
  53. A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China已完成NCT03565003研究中心I/II期2018-11 启动
  54. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  55. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  56. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma状态不明NCT02409186研究中心III期2015-03 启动
  57. Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma已完成NCT02395705研究中心III期2015-06 启动
  58. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT02611700研究中心III期2015-11 启动
  59. A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma状态不明NCT00642239研究中心IV期2008-04 启动
PubMed 以外找到的论文(未计入)62
  1. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncology论文
  2. 474TiP IDeate-Esophageal01: A phase III, randomized, open-label study of ifinatamab deruxtecan (I-DXd) in patients (pts) with pretreated advanced/metastatic esophageal squamous cell carcinoma (ESCC)2025Annals of Oncology论文
  3. 67eP ACR246, a novel 5T4 antibody-drug conjugate, showed promising anticancer efficacy in esophageal squamous cell carcinoma2025Annals of Oncology论文
  4. 963P SC-101, a Nectin-4-targeting peptide-drug conjugate (PDC), in patients (pts) with advanced or metastatic solid tumors: Results from dose escalation study2025Annals of Oncology论文
  5. A multi-epitope mRNA vaccine for effective immunotherapy in esophageal squamous cell carcinoma.2025Journal of Clinical Oncology论文
  6. Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): 2025Journal of Clinical Oncology会议摘要
  7. KEYMAKER-U06 substudy 06E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC2025Journal of Clinical Oncology论文
  8. LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomized phase III LEAP-014 study2025Annals of Oncology会议摘要
  9. PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study2025Journal of Thoracic Oncology论文
  10. Perioperative adebrelimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A single-arm, open-label, multicenter study.2025Journal of Clinical Oncology会议摘要
  11. The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.2025Journal of Clinical Oncology会议摘要
  12. 1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)2024Annals of Oncology论文
  13. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncology论文
  14. 265TiP Phase I/II open-label, umbrella platform designed study of investigational agents with or without pembrolizumab and/or chemotherapy in patients with advanced esophageal cancer previously treated with a PD-(L)1 inhibitor: KEYMAKER-U062024Annals of Oncology论文
  15. Abstract CT209: Camrelizumab plus chemotherapy as neoadjuvant treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): A single-center, randomized, phase II trial2024Cancer Research会议摘要
  16. Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncology会议摘要
  17. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncology会议摘要
  18. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Square预印本
  19. Octadecyl Gallate and Lipid‐Modified MnSe2 Nanoparticles Enhance Radiosensitivity in Esophageal Squamous Cell Carcinoma and Promote Radioprotection in Normal Tissues (Adv. Mater. 23/2024)2024Advanced Materials论文
  20. Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China.2024Journal of Clinical Oncology会议摘要
  21. SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncology会议摘要
  22. Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.2024Journal of Clinical Oncology会议摘要
  23. 1534P First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (mESCC): Safety run-in results from the phase III LEAP-014 study2023Annals of Oncology论文
  24. 189P Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncology论文
  25. Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-2023Cancer Research会议摘要
  26. Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis2023Cancer Research会议摘要
  27. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  28. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  29. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  30. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  31. Data from Long Noncoding RNA VESTAR Regulates Lymphangiogenesis and Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma by Enhancing VEGFC mRNA Stability2023未列出期刊其他
  32. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncology会议摘要
  33. MO19-4 Impact of tislelizumab on health-related quality of life in Asian patients with esophageal squamous cell carcinoma2023Annals of Oncology论文
  34. 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study2022Annals of Oncology论文
  35. 70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup2022Annals of Oncology论文
  36. 80P RATIONALE-302: Tislelizumab vs chemotherapy as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): Impact on health-related quality of life (HRQoL) in Asian patients2022Annals of Oncology论文
  37. ASO Visual Abstract: Combined Mean Corpuscular Hemoglobin, Fibrinogen, and Albumin (MF-A) Is a Novel Prognostic Marker in Patients with Resectable Esophageal Squamous Cell Carcinoma2022Annals of Surgical Oncology论文
  38. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  39. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  40. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  41. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  42. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figshare数据集
  43. First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress.2022Journal of Clinical Oncology会议摘要
  44. First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.2022Journal of Clinical Oncology会议摘要
  45. LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma.2022Journal of Clinical Oncology会议摘要
  46. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncology会议摘要
  47. P-298 Open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress2022Annals of Oncology会议摘要
  48. Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncology会议摘要
  49. Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncology会议摘要
  50. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).2022Journal of Clinical Oncology会议摘要
  51. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).2022Journal of Clinical Oncology会议摘要
  52. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncology论文
  53. 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha2021Annals of Oncology论文
  54. Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection2021International Journal of Radiation Oncology*Biology*Physics论文
  55. Determining an Evidence-Based Surveillance Target and Respective Intervals for Esophageal Squamous Cell Carcinoma Following Screening: A Population-Based Cohort Study in China2021SSRN Electronic Journal预印本
  56. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要
  57. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncology会议摘要
  58. Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.2021Journal of Clinical Oncology会议摘要
  59. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study2021Annals of Oncology会议摘要
  60. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figshare数据集
  61. O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup2021Annals of Oncology会议摘要
  62. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 42 篇,占 0.3%。

牵头论文
42
2021–2025 年
牵头试验
15
任何状态,ClinicalTrials.gov
牵头的开放试验
5
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 131320222023: 8820232024: 5520242025: 772025

北京有 17 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 11

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Phase I Study of OriC902 in Treatment of Advanced HCC
    分期
    I期
    开始
    2025-02
    登记号
    NCT06891742

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学肿瘤医院;另有 1 家列出的医院为研究中心北京

  2. 正在招募
    Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
    分期
    II期
    开始
    2024-01
    登记号
    NCT06360042

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院北京

  3. 正在招募
    Mts105 for Advanced Hepatocellular Carcinoma
    分期
    I期
    开始
    2024-11
    登记号
    NCT06689540

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院北京

  4. 正在招募
    Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
    分期
    II期
    开始
    2023-06
    登记号
    NCT05917431

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院北京

  5. 即将招募
    SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
    分期
    II期
    开始
    2026-10
    登记号
    NCT07882056

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院北京

  6. 正在招募
    Study of GV20-0251 in Participants With Solid Tumor Malignancies
    分期
    I/II期
    开始
    2025-07
    登记号
    NCT07070518

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京

  7. 正在招募
    A Study of DEG6498 in Participants With Solid Tumors
    分期
    I期
    开始
    2025-11
    登记号
    NCT07244835

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、广州

  8. 正在招募
    To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
    分期
    I期
    开始
    2025-08
    登记号
    NCT07594964

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京

  9. 正在招募
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    分期
    I期
    开始
    2022-10
    登记号
    NCT05208762

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京

  10. 正在招募
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
    分期
    I/II期
    开始
    2022-12
    登记号
    NCT05652920

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、成都、杭州、长春、长沙

  11. 即将招募
    A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
    分期
    I期
    开始
    2026-05
    登记号
    NCT07583316

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现免疫与靶向药物
论文中的科室影像/核医学科普外/肝胆胰外科放疗科肿瘤内科
牵头的论文42
  1. Negative 68Ga-FAPI-04 Uptake on PET/CT in HNF-1α-mutated Hepatocellular Adenoma: A Distinctive Feature for Differentiating From Hepatocellular Carcinoma.2026Clinical nuclear medicine
  2. Radiotherapy combined with anti-PD-1 immunotherapy promotes ferroptosis-driven control of hepatocellular carcinoma.2026Genes and immunity免费全文
  3. Effect of AFP and PIVKA-II secretion status on prognosis of advanced hepatocellular carcinoma patients receiving TACE combined with systemic therapy.2025BMC cancer免费全文
  4. Identification of Key Genes and Pathways in Lenvatinib-resistant Hepatocellular Carcinoma using Bioinformatic Analysis and Experimental Validation.2025Current medicinal chemistry
  5. SIRT4 Controls Acetyl-CoA Synthesis to Promote Stemness and Invasiveness of Hepatocellular Carcinoma through Deacetylating MCCC2.2025International journal of biological sciences免费全文
  6. Long non-coding RNA LINC01532 sustains redox homeostasis and accelerates lenvatinib resistance in hepatocellular carcinoma.2025Journal of advanced research免费全文
  7. The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial.2025Nature communications免费全文
  8. PFDN6L Gene Predicts Good Prognosis Associated with Its Inhibition of the Stem-Ness Properties in Hepatocellular Carcinoma.2025Oncology research免费全文
  9. Targeting NETO2 suppresses cell proliferation, invasion, and migration and inactivates the STAT3/C-MYC pathway in hepatocellular carcinoma.2025World journal of surgical oncology免费全文
  10. Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial.2024Clinical cancer research : an official journal of the American Association for Cancer Research
  11. GSTA1/CTNNB1 axis facilitates sorafenib resistance via suppressing ferroptosis in hepatocellular carcinoma.2024Pharmacological research
  12. A novel nomogram for prediction of intrahepatic recurrence-free survival in patients with HCC followed by radiofrequency ablation.2024The British journal of radiology免费全文
  13. Multimode Ultrasound Model for Predicting the Early Treatment Response of Anti-VEGF Agents Plus Anti-PD-1 Antibody in Patients with Unresectable Hepatocellular Carcinoma.2024Ultrasound in medicine & biology
  14. Evaluation of the Time Difference Method in Identifying Hepatocellular Carcinoma in Current CEUS LR-M Category Nodules.2024Ultrasound in medicine & biology
  15. Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma.2023Cell reports. Medicine免费全文
  16. Effect of vessels that encapsulate tumor clusters (VETC) on the prognosis of different stages of hepatocellular carcinoma after hepatectomy.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  17. An evaluation of 20-year survival of radiofrequency ablation for hepatocellular carcinoma as first-line treatment.2023European journal of radiology
  18. Evaluation of the safety and efficacy of ultrasound-guided percutaneous radiofrequency ablation for hepatocellular carcinoma and liver metastases adjacent to the gallbladder.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  19. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.2023Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT免费全文
  20. Activation of ACLY by SEC63 deploys metabolic reprogramming to facilitate hepatocellular carcinoma metastasis upon endoplasmic reticulum stress.2023Journal of experimental & clinical cancer research : CR免费全文
  21. Survival benefit of radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma: A propensity score-matched analysis based on phase II study.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  22. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.2023The Lancet. Oncology
  23. Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma.2022BMC cancer免费全文
  24. Liver tumor-initiating cells initiate the formation of a stiff cancer stem cell microenvironment niche by secreting LOX.2022Carcinogenesis
  25. A nomogram based on a three pyroptosis gene model and clinical parameters for predicting prognosis of hepatocellular carcinoma.2022Gene
  26. Diagnostic value of color parametric imaging and contrast-enhanced ultrasound in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma.2022Journal of clinical ultrasound : JCU
  27. PPP1R26 drives hepatocellular carcinoma progression by controlling glycolysis and epithelial-mesenchymal transition.2022Journal of experimental & clinical cancer research : CR免费全文
  28. Prognostic significance of albumin-bilirubin score in patients with unresectable hepatocellular carcinoma undergoing combined immunotherapy and radiotherapy.2022Journal of medical imaging and radiation oncology
  29. Hepatic Artery Injection of 131I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial.2022Journal of nuclear medicine : official publication, Society of Nuclear Medicine免费全文
  30. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.2022Molecular cancer免费全文
  31. Long non‑coding RNA LINC00238 suppresses the malignant phenotype of liver cancer by sponging miR‑522.2022Molecular medicine reports免费全文
  32. Long noncoding RNA LINC01234 promotes hepatocellular carcinoma progression through orchestrating aspartate metabolic reprogramming.2022Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  33. A Multicenter Randomized Controlled Study of Contrast-enhanced US versus US-guided Biopsy of Focal Liver Lesions.2022RadiologyRCT
  34. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.2022RadiologyRCT
  35. Computer-Aided Color Parameter Imaging of Contrast-Enhanced Ultrasound Evaluates Hepatocellular Carcinoma Hemodynamic Features and Predicts Radiofrequency Ablation Outcome.2022Ultrasound in medicine & biology
  36. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.2021BioMed research international免费全文
  37. The effect of propofol on the proliferation and apoptosis of hepatocellular carcinoma cells through TGF-Β1/Smad2 signaling pathway.2021Bioengineered免费全文
  38. Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance.2021British journal of cancer免费全文
  39. Epidemiology of Alcohol-Associated Liver Disease.2021Clinics in liver disease免费全文
  40. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.2021Immunotherapy
  41. γ-Glutamyltranspeptidase as a Prognostic Biomarker in Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.2021Journal of vascular and interventional radiology : JVIR
  42. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.2021Radiology
中文论文(未计入)1
  1. [Atezolizumab therapy in Chinese patients with locally advanced or metastatic solid tumors: An open-label, phase Ⅰ study].2022Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)50
  1. SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma即将招募NCT07882056牵头方II期2026-10 启动
  2. Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC正在招募NCT06360042牵头方II期2024-01 启动
  3. Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC正在招募NCT05917431牵头方II期2023-06 启动
  4. The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma状态不明NCT05862181牵头方2023-01 启动
  5. The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma已完成NCT04542837牵头方II期2020-09 启动
  6. Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection状态不明NCT02767375牵头方II/III期2015-02 启动
  7. A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients状态不明NCT02727309牵头方I/II期2015-10 启动
  8. The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma状态不明NCT03143140牵头方不分期2014-05 启动
  9. Phase I Study of OriC902 in Treatment of Advanced HCC正在招募NCT06891742牵头方(推断)I期2025-02 启动
  10. Mts105 for Advanced Hepatocellular Carcinoma正在招募NCT06689540牵头方(推断)I期2024-11 启动
  11. HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion进行中,不再招募NCT07466225牵头方(推断)2026-05 启动
  12. Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.已终止NCT05171166牵头方(推断)II/III期2021-12 启动
  13. Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma状态不明NCT04042805牵头方(推断)II期2019-08 启动
  14. Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis已完成NCT03009461牵头方(推断)II期2017-06 启动
  15. A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC状态不明NCT01997957牵头方(推断)IV期2013-10 启动
  16. A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors即将招募NCT07583316研究中心I期2026-05 启动
  17. A Study of DEG6498 in Participants With Solid Tumors正在招募NCT07244835研究中心I期2025-11 启动
  18. Study of GV20-0251 in Participants With Solid Tumor Malignancies正在招募NCT07070518研究中心I/II期2025-07 启动
  19. To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors正在招募NCT07594964研究中心I期2025-08 启动
  20. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors正在招募NCT05208762研究中心I期2022-10 启动
  21. Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC正在招募NCT05652920研究中心I/II期2022-12 启动
  22. A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC已撤回NCT05212922研究中心II期2023-06 启动
  23. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)进行中,不再招募NCT05904886研究中心III期2023-09 启动
  24. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma已终止NCT05653427研究中心II期2022-12 启动
  25. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  26. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev进行中,不再招募NCT04649489研究中心III期2021-04 启动
  27. Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)已完成NCT04740307研究中心II期2021-03 启动
  28. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  29. A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)已完成NCT04605796研究中心II期2020-04 启动
  30. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  31. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor进行中,不再招募NCT04008797研究中心I/II期2019-07 启动
  32. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  33. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  34. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  35. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)已完成NCT03867084研究中心III期2019-05 启动
  36. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  37. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)已完成NCT03713593研究中心III期2018-12 启动
  38. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动
  39. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma已完成NCT03434379研究中心III期2018-03 启动
  40. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)已完成NCT03062358研究中心III期2017-04 启动
  41. Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors状态不明NCT03507998研究中心I期2017-06 启动
  42. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  43. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects已终止NCT03236649研究中心III期2017-09 启动
  44. Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry已完成NCT03233360研究中心2017-04 启动
  45. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects状态不明NCT03236636研究中心III期2017-09 启动
  46. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma已完成NCT03113955研究中心不分期2017-10 启动
  47. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)已完成NCT02112656研究中心III期2014-06 启动
  48. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma已完成NCT01988493研究中心I/II期2014-01 启动
  49. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)已完成NCT00617981研究中心III期2008-05 启动
  50. T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients已终止NCT00057382研究中心II/III期2003-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 223 篇,占 2.3%。

牵头论文
223
2021–2025 年
牵头试验
53
任何状态,ClinicalTrials.gov
牵头的开放试验
9
正在或即将招募
作为研究中心的开放试验
33
由其他机构牵头
每年牵头的论文数
2021: 535320212022: 393920222023: 404020232024: 393920242025: 44442025

北京有 15 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 42

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    ctDNA-MRD Monitoring After Resection in Gastric Cancer
    分期
    未注明
    开始
    2025-04
    登记号
    NCT06893133

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院北京

  2. 正在招募
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    分期
    II期
    开始
    2025-12
    登记号
    NCT07127822

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院;另有 8 家列出的医院为研究中心北京、哈尔滨、天津、太原、成都、石家庄、西安、郑州、青岛

  3. 正在招募
    NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
    分期
    I期
    开始
    2024-11
    登记号
    NCT06134960

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学肿瘤医院北京

  4. 正在招募
    Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer
    分期
    不分期
    开始
    2024-06
    登记号
    NCT06306755

    年龄 50 岁 至 69 岁(登记的条件)

    牵头:北京大学肿瘤医院北京

  5. 正在招募
    Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
    分期
    不分期
    开始
    2024-08
    登记号
    NCT06429891

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:北京大学肿瘤医院北京

  6. 正在招募
    Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
    分期
    II期
    开始
    2024-09
    登记号
    NCT06580574

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院北京

  7. 正在招募
    Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
    分期
    II期
    开始
    2023-09
    登记号
    NCT06023758

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学肿瘤医院北京

  8. 正在招募
    Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
    分期
    不分期
    开始
    2019-09
    登记号
    NCT04047953

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学肿瘤医院北京

  9. 即将招募
    Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers
    分期
    未注明
    开始
    2026-06
    登记号
    NCT07656740

    年龄未注明(登记的条件)

    牵头:北京大学肿瘤医院北京

  10. 正在招募
    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
    分期
    II/III期
    开始
    2026-03
    登记号
    NCT07221149

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、南宁、广州、福州

  11. 正在招募
    A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-01
    登记号
    NCT07315750

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  12. 正在招募
    A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2026-01
    登记号
    NCT07354711

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  13. 正在招募
    LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
    分期
    III期
    开始
    2026-04
    登记号
    NCT07362186

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  14. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  15. 正在招募
    A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
    分期
    III期
    开始
    2026-05
    登记号
    NCT07518147

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  16. 正在招募
    Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
    分期
    III期
    开始
    2026-05
    登记号
    NCT07522151

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  17. 正在招募
    Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
    分期
    III期
    开始
    2026-09
    登记号
    NCT07700979

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、北京、广州

  18. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  19. 正在招募
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    分期
    III期
    开始
    2025-02
    登记号
    NCT06731478

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川

  20. 正在招募
    A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    分期
    II期
    开始
    2025-02
    登记号
    NCT06760819

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、杭州、长沙

  21. 正在招募
    BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
    分期
    I期
    开始
    2025-02
    登记号
    NCT06773312

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  22. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  23. 正在招募
    SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
    分期
    I期
    开始
    2025-02
    登记号
    NCT06873659

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、兰州、北京、南京、广州、杭州、济南、西安

  24. 正在招募
    A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
    分期
    III期
    开始
    2025-08
    登记号
    NCT07023315

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、哈尔滨、石家庄、福州

  25. 正在招募
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    分期
    I期
    开始
    2025-07
    登记号
    NCT07066657

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、哈尔滨、杭州、武汉、郑州、重庆、长沙

  26. 正在招募
    An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
    分期
    I/II期
    开始
    2025-12
    登记号
    NCT07371663

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、杭州、郑州

  27. 正在招募
    To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
    分期
    I期
    开始
    2025-08
    登记号
    NCT07594964

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京

  28. 正在招募
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    分期
    II/III期
    开始
    2024-02
    登记号
    NCT06221748

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、厦门、哈尔滨、徐州、成都、昆明、武汉、济南、郑州、长沙、青岛

  29. 正在招募
    Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
    分期
    I/II期
    开始
    2024-09
    登记号
    NCT06469944

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、厦门、杭州、福州、郑州

  30. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、洛阳、石家庄、福州、蚌埠、西宁、郑州、重庆、银川、长春、长沙、青岛

  31. 正在招募
    A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
    分期
    未注明
    开始
    2024-12
    登记号
    NCT07547787

    年龄未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  32. 正在招募
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    分期
    未注明
    开始
    2023-01
    登记号
    NCT05722275

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、太原、广州、昆明、福州、郑州

  33. 正在招募
    A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
    分期
    II期
    开始
    2023-11
    登记号
    NCT06008054

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  34. 正在招募
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    分期
    未注明
    开始
    2023-09
    登记号
    NCT06035250

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛

  35. 正在招募
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    II期
    开始
    2023-11
    登记号
    NCT06155383

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、厦门、哈尔滨、广州、成都、昆明、济南、福州、郑州

  36. 正在招募
    M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
    分期
    III期
    开始
    2023-12
    登记号
    NCT06177041

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  37. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

  38. 正在招募
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    分期
    I期
    开始
    2022-10
    登记号
    NCT05208762

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京

  39. 正在招募
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
    分期
    I期
    开始
    2022-02
    登记号
    NCT05262491

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、南昌、天津、成都、杭州、济南

  40. 正在招募
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    分期
    I期
    开始
    2021-06
    登记号
    NCT04900818

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、郑州

  41. 即将招募
    A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
    分期
    III期
    开始
    2025-05
    登记号
    NCT06944496

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  42. 即将招募
    A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
    分期
    I期
    开始
    2024-11
    登记号
    NCT06614751

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期免疫与靶向药物化疗与综合治疗
论文中的科室肿瘤内科影像/核医学科病理/检验科放疗科
牵头的论文223
  1. Discordance in tumour response assessment for gastric cancer after neoadjuvant chemotherapy using different methods.2026Abdominal radiology (New York)
  2. Characterization of Microplastics in Human Gastric Cancer and Control Tissues and Analysis of Associated Genetic Features.2026Advanced healthcare materials免费全文
  3. TOPK Inhibition Promotes Anti-Tumor Immunity Via eIF4F Complex Mediated STAT1 Translation in Gastric Cancer.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  4. Impact of concomitant medications on efficacy of CLDN18.2-specific CAR-T cell therapy in advanced gastric cancer.2026British journal of cancer
  5. Predicting 177Lu-DOTATATE therapy response through immune microenvironment parameters in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).2026European journal of nuclear medicine and molecular imaging
  6. Postoperative infectious complications in gastric and colorectal cancer patients: A multicenter prospective cohort study from China.2026Surgery
  7. Comparison of postoperative reflux esophagitis in different digestive tract reconstruction methods after proximal gastrectomy for proximal gastric cancer patients: a network meta-analysis and systematic review.2026Updates in surgery
  8. Histological and biomarker landscape of Claudin18.2-positive gastric and gastroesophageal junction cancers: a study of 937 cases.2026Virchows Archiv : an international journal of pathology
  9. A CLDN18.2-Targeted Nanoplatform Manipulates Magnetic Hyperthermia Spatiotemporally for Synergistic Immunotherapy in Gastric Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  10. Utilizing Combined Circulating Tumor DNA and Tumor Markers to Evaluate Neoadjuvant Therapy Response and Predict Recurrence in Patients with Locally Advanced Gastric Cancer.2025Annals of surgical oncology
  11. The value of translational therapy in the treatment of advanced hepatoid adenocarcinoma of stomach.2025BMC cancer免费全文
  12. Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers.2025BMC cancer免费全文
  13. Clinicopathologic characteristics and prognostic factors of pure gastric neuroendocrine carcinoma patients undergoing radical surgery.2025BMC cancer免费全文
  14. Comprehensive evaluation of tumor response better evaluates the efficacy of neoadjuvant chemotherapy and predicts the prognosis in gastric cancer - a post hoc analysis of a single-center randomized controlled trial.2025BMC cancerRCT免费全文
  15. Immune microenvironment spatial landscapes of tertiary lymphoid structures in gastric cancer.2025BMC medicine免费全文
  16. Comparison of the safety of esophagojejunal overlap and π-shaped anastomosis in totally laparoscopic total gastrectomy.2025BMC surgery免费全文
  17. Effect of risk-based screening for upper gastrointestinal cancers: a multi-center real-world study.2025British journal of cancer免费全文
  18. Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer.2025British journal of cancer免费全文
  19. Proteomic profiling and scRNA sequencing identify signatures associated with Helicobacter pylori infection and risk of developing gastric cancer.2025Cancer biology & medicine免费全文
  20. Plasma L-aspartic acid predicts the risk of gastric cancer and modifies the primary prevention effect: a multistage metabolomic profiling and Mendelian randomization study.2025Cancer biology & medicine免费全文
  21. Advances and challenges in gastric cancer testing: the role of biomarkers.2025Cancer biology & medicine免费全文
  22. Harnessing exosomes: From tumor immune escape to therapeutic innovation in gastric cancer immunotherapy.2025Cancer letters
  23. Hepatoid adenocarcinoma of the stomach and non-hepatoid alpha-fetoprotein-producing gastric cancer exhibit a high degree of molecular similarity.2025Cellular oncology (Dordrecht, Netherlands)免费全文
  24. Feasibility and long-term survival of proximal gastrectomy after neoadjuvant therapy for locally advanced proximal gastric cancer: A propensity-score-matched analysis.2025Chinese medical journal免费全文
  25. Ginkgolide B Inhibits EMT and Promotes Pyroptosis in Gastric Cancer via AKT/mTOR Pathway.2025Drug design, development and therapy免费全文
  26. Integrating genetics and transcriptomics to decipher susceptibility genes for risk stratification of gastric cancer and effect modification of Helicobacter pylori treatment.2025EBioMedicine免费全文
  27. Computed tomography features of gastric cancer with deficient mismatch repair: Radiologic-pathologic correlation.2025European journal of radiology
  28. Identifying potential beneficiaries of neoadjuvant therapy in borrmann type III and IV gastric cancer: A treatment heterogeneity analysis using causal survival forests.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  29. CT radiomics-based intratumoral and intertumoral heterogeneity indicators for prognosis prediction in gastric cancer patients receiving neoadjuvant chemotherapy.2025European radiology
  30. Multi-omic profiling identifies KRT1 as a predictor of immune infiltration and prognosis in gastroesophageal junction cancer.2025Functional & integrative genomics
  31. Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  32. Host Genetic Variants Associated With Helicobacter pylori Infection: A Meta-Analysis Combined With Functional Annotation.2025Helicobacter
  33. Enhanced HER2 status detection in breast and gastric cancers using surrogate DNA methylation markers.2025IUBMB life
  34. Integrative metabolomics and microbiomics analysis reveals distinctive microbiota-metabolites interactions in gastric carcinogenesis.2025International journal of cancer
  35. First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.2025JAMARCT免费全文
  36. Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial.2025JAMA oncologyRCT免费全文
  37. Impact of Psychological Factors on Survival in Metastatic Esophagogastric Cancer: Secondary Analysis of a Randomized Controlled Trial.2025JCO oncology practiceRCT
  38. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis.2025Journal of hematology & oncology免费全文
  39. Short-term outcomes of robotic versus laparoscopic gastrectomy for proximal gastric cancer: a systematic review and meta-analysis of propensity score-matched or baseline-balanced retrospective studies.2025Journal of robotic surgery
  40. Laparoscopic vs robot-assisted gastrectomy in gastric cancer patients with prior abdominal surgery: a propensity-matched analysis.2025Journal of robotic surgery
  41. Serum miR-30c serves as potential biomarkers for the diagnosis and prognosis of gastric cancer.2025Journal of toxicology and environmental health. Part A
  42. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.2025Lancet (London, England)RCT
  43. Advances in the study of the role of gastric microbiota in the progression of gastric cancer.2025Microbial pathogenesis
  44. The accumulation of myeloid-derived suppressor cells participates in abdominal infection-induced tumor progression through the PD-L1/PD-1 axis.2025Molecular oncology免费全文
  45. CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial.2025Nature medicine免费全文
  46. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.2025Nature medicineRCT
  47. Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value.2025Scientific reports免费全文
  48. PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial.2025Signal transduction and targeted therapy免费全文
  49. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final re2025The Lancet. OncologyRCT
  50. Noninvasive in vivo tracking of SPIONs-labeled CLDN18.2-targeted CAR-T cells in gastric cancer via magnetic particle imaging.2025Translational research : the journal of laboratory and clinical medicine
  51. Diagnostic accuracy of stereomicroscopy assessment of invasion depth in ex vivo specimens of early gastric cancer.2025World journal of gastroenterology免费全文
  52. Lymph node metastatic patterns of gastric carcinoma with a combination of adenocarcinoma and neuroendocrine carcinoma components.2025World journal of gastroenterology免费全文
  53. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.2024Advances in therapy免费全文
  54. Pre- and Post-treatment Double-Sequential-Point Dynamic Radiomic Model in the Response Prediction of Gastric Cancer to Neoadjuvant Chemotherapy: 3-Year Survival Analysis.2024Annals of surgical oncology
  55. A modified esophagogastric reconstruction method after laparoscopic proximal gastrectomy: A technical note with video vignette.2024Asian journal of surgery
  56. Long-term outcomes of laparoscopic versus open total gastrectomy in patients with advanced gastric cancer after neoadjuvant chemotherapy: a retrospective cohort study.2024BMC cancer免费全文
  57. Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer.2024British journal of cancer免费全文
  58. Advances in MET tyrosine kinase inhibitors in gastric cancer.2024Cancer biology & medicine免费全文
  59. Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers.2024Cancer immunology, immunotherapy : CII免费全文
  60. Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.2024Cancer immunology, immunotherapy : CII免费全文
  61. Phase I study of BC001, a novel fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, in advanced solid tumors.2024Cancer medicine免费全文
  62. Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression.2024Cell communication and signaling : CCS免费全文
  63. Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomach.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  64. Development and external validation of a quantitative diagnostic model for malignant gastric lesions in clinical opportunistic screening: A multicenter real-world study.2024Chinese medical journal免费全文
  65. Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis.2024Clinical and translational medicine免费全文
  66. ABCC2 induces metabolic vulnerability and cellular ferroptosis via enhanced glutathione efflux in gastric cancer.2024Clinical and translational medicine免费全文
  67. Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification.2024Clinical and translational science免费全文
  68. [177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models.2024European journal of nuclear medicine and molecular imaging
  69. MiRNA29a-3p negatively regulates ISL1-Integrin β1 axis to suppress gastric cancer progression.2024Experimental cell research
  70. CDKN2A somatic copy number amplification in normal tissues surrounding gastric carcinoma reduces cancer metastasis risk in droplet digital PCR analysis.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  71. Specific lineage transition of tumor-associated macrophages elicits immune evasion of ascitic tumor cells in gastric cancer with peritoneal metastasis.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  72. Intratumoral microbiome is associated with gastric cancer prognosis and therapy efficacy.2024Gut microbes免费全文
  73. Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapy.2024Human cell免费全文
  74. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort.2024Human pathology
  75. The tumor immune microenvironment remodeling and response to HER2-targeted therapy in HER2-positive advanced gastric cancer.2024IUBMB life
  76. A noninvasive multianalytical approach establishment for risk assessment and gastric cancer screening.2024International journal of cancer
  77. Multiple approaches revealed MGc80-3 as a somatic hybrid with HeLa cells rather than a gastric cancer cell line.2024International journal of cancer
  78. Helicobacter pylori Treatment and Gastric Cancer Risk Among Individuals With High Genetic Risk for Gastric Cancer.2024JAMA network open免费全文
  79. Dynamic change in the peritoneal cancer index based on CT after chemotherapy in the overall survival prediction of gastric cancer patients with peritoneal metastasis.2024Journal of cancer research and clinical oncology免费全文
  80. Analyzing the associations between tertiary lymphoid structures and postoperative prognosis, along with immunotherapy response in gastric cancer: findings from pooled cohort studies.2024Journal of cancer research and clinical oncology免费全文
  81. The deubiquitinase USP15 drives malignant progression of gastric cancer through glucose metabolism remodeling.2024Journal of experimental & clinical cancer research : CR免费全文
  82. Advanced Gastric Cancer: CT Radiomics Prediction of Lymph Modes Metastasis After Neoadjuvant Chemotherapy.2024Journal of imaging informatics in medicine免费全文
  83. Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancer.2024Molecular cancer免费全文
  84. Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.2024Nature medicineRCT
  85. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.2024Nature medicine
  86. Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data.2024Signal transduction and targeted therapy免费全文
  87. Long-term outcomes of laparoscopic versus open distal gastrectomy for patients with advanced gastric cancer in North China: a multicenter randomized controlled trial.2024Surgical endoscopyRCT免费全文
  88. Risk factors and clinical significance of lower perigastric lymph node metastases in Siewert type II and III esophagogastric junction adenocarcinoma: a retrospective cohort study.2024Surgical endoscopy免费全文
  89. Safety and short-term outcomes of a modified valvuloplastic esophagogastrostomy versus gastric tube anastomosis after laparoscopy-assisted proximal gastrectomy: a retrospective cohort study.2024Surgical endoscopy免费全文
  90. Multi-regional sequencing reveals the genetic and immune heterogeneity of non-cancerous tissues in gastric cancer.2024The Journal of pathology
  91. Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases.2024The journal of pathology. Clinical research免费全文
  92. Targeting SALL4 by Entinostat Inhibits the Malignant Phenotype of Gastric Cancer Cells by Reducing EMT Signaling.2023Anticancer research
  93. Prognostic significance of preoperative serum tumor markers in hepatoid adenocarcinoma of stomach (HAS).2023BMC cancer免费全文
  94. Analysis of enhanced CT imaging signs and clinicopathological prognostic factors in hepatoid adenocarcinoma of stomach patients with radical surgery: a retrospective study.2023BMC medical imaging免费全文
  95. Identification of Immunogenic Cell-Death-Related Subtypes and Development of a Prognostic Signature in Gastric Cancer.2023Biomolecules免费全文
  96. From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space.2023Cancer cell
  97. Kinase D-interacting Substrate of 220 kDa Is Overexpressed in Gastric Cancer and Associated With Local Invasion.2023Cancer genomics & proteomics免费全文
  98. Pulmonary lymphangitis carcinomatosis: A peculiar presentation clustering in MET-amplified gastric cancer.2023Cancer medicine免费全文
  99. Tumor regression grade combined with post-therapy lymph node status: A novel independent prognostic factor for patients treated with neoadjuvant therapy followed by surgery in locally advanced gastroesophageal junction and gastric carcinoma2023Cancer medicine免费全文
  100. T-cells infiltration mediates the association between neutrophil/lymphocyte ratio and survival in gastric cancer.2023Cancer medicine免费全文
  101. Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results.2023Cancer medicineRCT
  102. Gastric cancer-associated long non-coding RNA profiling and noninvasive biomarker screening based on a high-risk population cohort.2023Cancer medicine免费全文
  103. Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I study.2023Cancer medicine免费全文
  104. The N6-methyladenine DNA demethylase ALKBH1 promotes gastric carcinogenesis by disrupting NRF1 binding capacity.2023Cell reports
  105. Next stage of collaboration in East Asia gastric cancer treatment.2023Chinese clinical oncology
  106. Global burden prediction of gastric cancer during demographic transition from 2020 to 2040.2023Chinese medical journal免费全文
  107. The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer.2023Clinical and translational medicine免费全文
  108. Multidimensional immune profiling in Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital project informs PD-1/PD-L1 blockade efficacy.2023European journal of cancer (Oxford, England : 1990)
  109. First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection.2023European journal of nuclear medicine and molecular imaging
  110. Death receptor 5 promotes tumor progression in gastric cancer.2023FEBS open bio免费全文
  111. Time to surgery does not affect oncologic outcomes in locally advanced gastric cancer after neoadjuvant chemotherapy: a meta-analysis.2023Future oncology (London, England)
  112. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.2023International journal of cancerRCT免费全文
  113. China special issue on gastrointestinal tumors-Improved survival after multidisciplinary team decision for patients with advanced gastrointestinal cancer: A multicenter, noninterventional, controlled study.2023International journal of cancer
  114. Using Normalized Carcinoembryonic Antigen and Carbohydrate Antigen 19 to Predict and Monitor the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.2023International journal of molecular sciences免费全文
  115. Aspartate β-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer.2023International journal of molecular sciences免费全文
  116. Long-term health-related quality of life in patients with gastric cancer after total or distal gastrectomy: a propensity score-matched cohort study.2023International journal of surgery (London, England)免费全文
  117. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.2023Journal for immunotherapy of cancer免费全文
  118. Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade.2023Journal for immunotherapy of cancer免费全文
  119. Discrimination of Liver Metastases of Digestive System Neuroendocrine Tumors From Neuroendocrine Carcinoma by Computed Tomography-Based Radiomics Analysis.2023Journal of computer assisted tomography
  120. Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study.2023Journal of medical genetics免费全文
  121. Efficacy and safety of preoperative immunotherapy alone followed by surgery in the treatment of advanced gastric cancer with MSI-H/dMMR or EBV-positive.2023Journal of the Chinese Medical Association : JCMA免费全文
  122. Transcriptome profiling of patient-derived tumor xenografts suggests novel extracellular matrix-related signatures for gastric cancer prognosis prediction.2023Journal of translational medicine免费全文
  123. Metabolite Alterations and Interactions with Microbiota in Helicobacter pylori-Associated Gastric Lesions.2023Microbiology spectrum免费全文
  124. Label-free serum proteomics for the identification of the putative biomarkers of postoperative pain in patients with gastric cancer.2023Molecular omics
  125. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer.2023Molecular oncology免费全文
  126. Piceatannol enhances Beclin-1 activity to suppress tumor progression and its combination therapy strategy with everolimus in gastric cancer.2023Science China. Life sciences
  127. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance.2023Signal transduction and targeted therapy免费全文
  128. Allium vegetable intake associated with the risk of incident gastric cancer: a continuous follow-up study of a randomized intervention trial.2023The American journal of clinical nutritionRCT
  129. An exploration of gastric cancer with heterogeneous mismatch repair status.2023Virchows Archiv : an international journal of pathology
  130. Prognostic nomograms for gastric carcinoma after D2 + total gastrectomy to assist decision-making for postoperative treatment: based on Lasso regression.2023World journal of surgical oncology免费全文
  131. Efficacy of chemotherapy versus surgery as initial treatment for gastric cancer with positive peritoneal cytology.2023World journal of surgical oncology免费全文
  132. Response to the rechallenge of combination immunotherapy in a patient with late-stage gastric cancer: case report.2022Annals of palliative medicine
  133. Early Diagnosis of Anastomotic Leakage After Gastric Cancer Surgery Via Analysis of Inflammatory Factors in Abdominal Drainage.2022Annals of surgical oncology
  134. Associations of Annual Hospital and Surgeon Volume with Patient Outcomes After Gastrectomy: A Systematic Review and Meta-analysis.2022Annals of surgical oncology
  135. Safety and short-term outcomes of gastrectomy after preoperative chemotherapy plus immunotherapy versus preoperative chemotherapy: a retrospective cohort study.2022BMC cancer免费全文
  136. The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study.2022BMC cancer免费全文
  137. A potential decision-making algorithm based on endoscopic ultrasound for staging early gastric cancer: a retrospective study.2022BMC cancer免费全文
  138. A 9‑gene expression signature to predict stage development in resectable stomach adenocarcinoma.2022BMC gastroenterology免费全文
  139. Epstein-Barr virus-associated gastric adenosquamous carcinoma with concurrent gastric carcinoma with lymphoid stroma: a case report and review of the literature.2022BMC gastroenterology免费全文
  140. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.2022BMC medicine免费全文
  141. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.2022BMC medicine免费全文
  142. Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma.2022BMC medicine免费全文
  143. Clinical Significance and Immune Infiltration Analyses of the Cuproptosis-Related Human Copper Proteome in Gastric Cancer.2022Biomolecules免费全文
  144. Early detection of gastric cancer in China: progress and opportunities.2022Cancer biology & medicine免费全文
  145. SDCBP-AS1 destabilizes β-catenin by regulating ubiquitination and SUMOylation of hnRNP K to suppress gastric tumorigenicity and metastasis.2022Cancer communications (London, England)免费全文
  146. Urine proteomic signatures predicting the progression from premalignancy to malignant gastric cancer.2022EBioMedicine免费全文
  147. Beneficial effects of endoscopic screening on gastric cancer and optimal screening interval: a population-based study.2022Endoscopy
  148. Psychological distress and resilience in patients with gastroenteropancreatic neuroendocrine tumor.2022Frontiers in endocrinology免费全文
  149. The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  150. miRNAs derived from plasma small extracellular vesicles predict organo-tropic metastasis of gastric cancer.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  151. JAK-STAT1 Signaling Pathway Is an Early Response to Helicobacter pylori Infection and Contributes to Immune Escape and Gastric Carcinogenesis.2022International journal of molecular sciences免费全文
  152. Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis.2022Journal for immunotherapy of cancer免费全文
  153. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.2022Journal for immunotherapy of cancer免费全文
  154. Successful treatment of a case with synchronous follicular lymphoma and gastric adenocarcinoma with CD19 CAR T cells and literature review.2022Journal of clinical pharmacy and therapeutics
  155. Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer.2022Journal of extracellular vesicles免费全文
  156. Interpretable tumor differentiation grade and microsatellite instability recognition in gastric cancer using deep learning.2022Laboratory investigation; a journal of technical methods and pathology
  157. Omitting nasogastric tube placement after gastrectomy does not enhance postoperative recovery: a propensity score matched analysis.2022Langenbeck's archives of surgery
  158. A liquid biopsy signature of circulating exosome-derived mRNAs, miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer.2022Molecular cancer免费全文
  159. Targeting Claudin 18.2 Using a Highly Specific Antibody Enables Cancer Diagnosis and Guided Surgery.2022Molecular pharmaceutics
  160. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment.2022Nature communications免费全文
  161. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.2022Nature medicine免费全文
  162. Gamma-glutamyltransferase 7 suppresses gastric cancer by cooperating with RAB7 to induce mitophagy.2022Oncogene
  163. Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer.2022Oncoimmunology免费全文
  164. Identification of Preoperative Serum Metabolites Associated With Postoperative Opioid Consumption in Gastric Cancer Patients by Extreme Phenotype Sampling.2022Pain physician
  165. Dual roles of β-arrestin 1 in mediating cell metabolism and proliferation in gastric cancer.2022Proceedings of the National Academy of Sciences of the United States of America免费全文
  166. Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study.2022Radiation oncology (London, England)免费全文
  167. Modified π-shaped esophagojejunostomy in totally laparoscopic total gastrectomy: a report of 40 consecutive cases from a single center.2022The Journal of international medical research免费全文
  168. Plasma lipids signify the progression of precancerous gastric lesions to gastric cancer: a prospective targeted lipidomics study.2022Theranostics免费全文
  169. Feasibility of same-day discharge following endoscopic submucosal dissection for esophageal or gastric early cancer.2022World journal of gastroenterology免费全文
  170. Short-and long-term outcomes of laparoscopic versus open gastrectomy in patients with gastric cancer: a systematic review and meta-analysis of randomized controlled trials.2022World journal of surgical oncology免费全文
  171. Role of CT in the prediction of pathological complete response in gastric cancer after neoadjuvant chemotherapy.2021Abdominal radiology (New York)
  172. Utility of the gastric window in computed tomography for differentiation of early gastric cancer (T1 stage) from muscularis involvement (T2 stage).2021Abdominal radiology (New York)
  173. Ultrasensitive Gastric Cancer Circulating Tumor Cellular CLDN18.2 RNA Detection Based on a Molecular Beacon.2021Analytical chemistry
  174. Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.2021Annals of surgical oncology免费全文
  175. Construction and Validation of a Risk-Scoring Model that Preoperatively Predicts Lymph Node Metastasis in Early Gastric Cancer Patients.2021Annals of surgical oncology
  176. Effect of Additional Trastuzumab in Neoadjuvant and Adjuvant Treatment for Patients with Resectable HER2-Positive Gastric Cancer.2021Annals of surgical oncology
  177. The T-Cell-Inflammation Status Can Predict Outcomes of Adjuvant Chemotherapy in Patients with Gastric Cancer.2021Annals of surgical oncology
  178. Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study.2021BMC cancer免费全文
  179. DNA methylation signatures associated with prognosis of gastric cancer.2021BMC cancer免费全文
  180. Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery.2021BMC cancerRCT免费全文
  181. Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment.2021BMC gastroenterology免费全文
  182. Development and validation of a novel staging system integrating the number and location of lymph nodes for gastric adenocarcinoma.2021British journal of cancer免费全文
  183. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.2021Cancer communications (London, England)免费全文
  184. Insulin gene enhancer protein 1 mediates glycolysis and tumorigenesis of gastric cancer through regulating glucose transporter 4.2021Cancer communications (London, England)免费全文
  185. Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients.2021Cancer letters
  186. Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasm.2021Cancer medicine免费全文
  187. Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities.2021Cancer medicine免费全文
  188. Double Tract Reconstruction Reduces Reflux Esophagitis and Improves Quality of Life after Radical Proximal Gastrectomy for Patients with Upper Gastric or Esophagogastric Adenocarcinoma.2021Cancer research and treatment免费全文
  189. An Innovative Prognostic Model Based on Four Genes in Asian Patient with Gastric Cancer.2021Cancer research and treatment免费全文
  190. EGR1-mediated linc01503 promotes cell cycle progression and tumorigenesis in gastric cancer.2021Cell proliferation免费全文
  191. Comparison of neoadjuvant chemotherapy followed by surgery vs. surgery alone for locally advanced gastric cancer: a meta-analysis.2021Chinese medical journal免费全文
  192. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.2021Clinical cancer research : an official journal of the American Association for Cancer Research
  193. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.2021Diagnostic pathology免费全文
  194. Effect of administration of a proton pump inhibitor for ulcerative differentiated early gastric cancer prior to endoscopic submucosal dissection.2021Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  195. Proteomic profiling identifies signatures associated with progression of precancerous gastric lesions and risk of early gastric cancer.2021EBioMedicine免费全文
  196. Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring.2021European journal of nuclear medicine and molecular imaging
  197. Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?2021European journal of radiology
  198. Comparison of totally laparoscopic and laparoscopic assisted gastrectomy after neoadjuvant chemotherapy in locally advanced gastric cancer.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  199. Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  200. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association免费全文
  201. Deep learning system for lymph node quantification and metastatic cancer identification from whole-slide pathology images.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  202. ASB16-AS1 up-regulated and phosphorylated TRIM37 to activate NF-κB pathway and promote proliferation, stemness, and cisplatin resistance of gastric cancer.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  203. Profiling heterogenous sizes of circulating tumor microemboli to track therapeutic resistance and prognosis in advanced gastric cancer.2021Human cell免费全文
  204. CXCL16 Promotes Gastric Cancer Tumorigenesis via ADAM10-Dependent CXCL16/CXCR6 Axis and Activates Akt and MAPK Signaling Pathways.2021International journal of biological sciences免费全文
  205. MicroRNA-135b/CAMK2D Axis Contribute to Malignant Progression of Gastric Cancer through EMT Process Remodeling.2021International journal of biological sciences免费全文
  206. Identification and Validation of Plasma Metabolomic Signatures in Precancerous Gastric Lesions That Progress to Cancer.2021JAMA network open免费全文
  207. Effects of laparoscopic-assisted gastrectomy on elderly patients with gastric cancer.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  208. Surgical and oncological efficacy of laparoscopic-assisted total gastrectomy versus open total gastrectomy for gastric cancer by propensity score matching: a retrospective comparative study.2021Journal of cancer research and clinical oncology免费全文
  209. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial.2021Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT免费全文
  210. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.2021Journal of hematology & oncology免费全文
  211. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.2021Journal of molecular medicine (Berlin, Germany)
  212. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.2021Journal of surgical oncology
  213. Short-term outcomes after totally laparoscopic total gastrectomy with esophagojejunostomy constructed by π-shaped method versus overlap method.2021Journal of surgical oncology
  214. Comparison of the short-term outcomes of laparoscopic and open total or proximal gastrectomy using the transorally inserted anvil (OrVilTM) for the proximal reconstruction: a propensity score matching analysis.2021Langenbeck's archives of surgery
  215. Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications.2021Molecular cancer免费全文
  216. Association of serotonin transporter-linked polymorphic region (5-HTTLPR) with heat pain stimulation and postoperative pain in gastric cancer patients.2021Molecular pain免费全文
  217. Genomic and transcriptomic profiling of hepatoid adenocarcinoma of the stomach.2021Oncogene
  218. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.2021Oncogene
  219. Proteomics provides individualized options of precision medicine for patients with gastric cancer.2021Science China. Life sciences
  220. Risk factors for esophagojejunal anastomotic leakage after curative total gastrectomy combined with D2 lymph node dissection for gastric cancer.2021The Journal of international medical research免费全文
  221. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-2021The Lancet. OncologyRCT
  222. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 t2021The lancet. Gastroenterology & hepatologyRCT
  223. Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).2021The oncologist免费全文
中文论文(未计入)20
  1. [Development and dissemination of precision medicine approaches in gastric cancer management].2025Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences免费全文
  2. [Development status and prospects of functional preservation surgery for gastric cancer].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Precise diagnosis and treatment strategies for gastric cancer guided by clinical issues].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Tissue and plasma proteomic signatures associated with the risk of gastric cancer].2025Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
  5. [Surgical management of gastric cancer in the era of immunotherapy].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  6. [Analysis of the efficacy and safety of preoperative programmed death protein-1 inhibitor combined with chemotherapy in immunotherapy-sensitive patients with locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction]2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Neoadjuvant immunotherapy ushers in a new era of gastric cancer treatment].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Impact and intervention of postoperative complications after gastric cancer surgery from a health economics perspective].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Regarding the selection of individualized therapy after neoadjuvant therapy for gastrointestinal tumors].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. [Incidence of postoperative complications in Chinese patients with gastric or colorectal cancer based on a national, multicenter, prospective, cohort study].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  11. [Quality control in the establishment and management of gastric cancer database].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  12. [Interpretation on the report of global cancer statistics 2022].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  13. [Clinicopathological characteristics of gastric SMARCA4-deficient undifferentiated/rhabdoid carcinoma].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  14. [Building world leading surgical oncology for gastric cancer in China].2023Zhonghua wai ke za zhi [Chinese journal of surgery]
  15. [Surveys on diagnosis and treatment of esophagogastric junction adenocarcinoma by the Chinese Laparoscopic Gastrointestinal Surgery Study Group-10 Research Team].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  16. [The risk of incident gastric cancer for populations with different precancerous gastric lesions: a prospective follow-up study].2022Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  17. [Dissection borders of laparoscopic lower mediastinal lymphadenectomy for adenocarcinoma of esophagogastric junction and the quality control].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  18. [Accurate diagnosis and individualized treatment of advanced gastric cancer: pathological detection of biomarkers based on cancer tissue samples].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  19. [Progress in gastric cancer with positive peritoneal cytology].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  20. [Implementation strategy of enhanced recovery after surgery in perioperative management of gastric cancer].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)147
  1. Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers即将招募NCT07656740牵头方2026-06 启动
  2. Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer正在招募NCT06306755牵头方不分期2024-06 启动
  3. Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma正在招募NCT04047953牵头方不分期2019-09 启动
  4. Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma状态不明NCT05816863牵头方2023-03 启动
  5. Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors状态不明NCT04764084牵头方I期2021-04 启动
  6. Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for AGC状态不明NCT03708783牵头方不分期2018-07 启动
  7. Quality of Life in Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy状态不明NCT04408859牵头方2018-04 启动
  8. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer已终止NCT02867839牵头方III期2017-04 启动
  9. Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer已完成NCT03425058牵头方2017-11 启动
  10. Effect of Laparoscopy-Assisted Distal Gastrectomy for Locally Advanced Gastric Cancer状态不明NCT02464215牵头方不分期2014-03 启动
  11. DNA Methylation Biomarkers and Metastasis of Gastric Carcinoma已完成NCT02159339牵头方2012-12 启动
  12. Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis状态不明NCT01167049牵头方II期2009-08 启动
  13. ctDNA-MRD Monitoring After Resection in Gastric Cancer正在招募NCT06893133牵头方(推断)2025-04 启动
  14. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer正在招募NCT07127822牵头方(推断)II期2025-12 启动
  15. NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor正在招募NCT06134960牵头方(推断)I期2024-11 启动
  16. Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers正在招募NCT06580574牵头方(推断)II期2024-09 启动
  17. Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization正在招募NCT06429891牵头方(推断)不分期2024-08 启动
  18. Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC正在招募NCT06023758牵头方(推断)II期2023-09 启动
  19. Perioperative Cadonilimab (AK104) in Locally Advanced MSI-H/dMMR Gastric or Gastroesophageal Junction and Colorectal Adenocarcinoma进行中,不再招募NCT04556253牵头方(推断)II期2024-02 启动
  20. Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA状态不明NCT06222944牵头方(推断)II期2024-02 启动
  21. The Effect of MDT Plus SDM on Survival Benefit of Advanced Gastric Cancer状态不明NCT06432205牵头方(推断)2023-11 启动
  22. Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy状态不明NCT05649163牵头方(推断)2023-01 启动
  23. Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors状态不明NCT05393986牵头方(推断)I期2022-08 启动
  24. Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System状态不明NCT05165602牵头方(推断)2022-01 启动
  25. Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer状态不明NCT05227378牵头方(推断)不分期2022-03 启动
  26. Selecting Patients Who May Benefit From Immunotherapy by Tissue-based Biomarkers.状态不明NCT05593419牵头方(推断)2022-10 启动
  27. Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer状态不明NCT04777162牵头方(推断)II期2021-03 启动
  28. Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach已撤回NCT04863430牵头方(推断)II期2021-05 启动
  29. Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics状态不明NCT04584008牵头方(推断)不分期2020-09 启动
  30. Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma状态不明NCT04609176牵头方(推断)II期2020-11 启动
  31. Laparoscopic Versus Open Lower Mediastinal Lymphadenectomy for Esophagogastric Junction Cancer状态不明NCT04443478牵头方(推断)2020-08 启动
  32. Study on the Effectiveness of Gastroscope Operation Quality Control Based on Artificial Intelligence Technology已完成NCT04384575牵头方(推断)2020-02 启动
  33. Function Preserving Gastrectomy for T1/2 Gastric Cancer Patients状态不明NCT03874871牵头方(推断)2019-03 启动
  34. Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer状态不明NCT04202601牵头方(推断)I/II期2019-12 启动
  35. Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer状态不明NCT05348161牵头方(推断)不分期2019-01 启动
  36. Real World Evidence for the Cycle of Neoadjuvant Chemotherapy in Gastric Cancer With Shared Decision Making状态不明NCT03413514牵头方(推断)不分期2018-01 启动
  37. Verifying the Specificity of a New Method in Predicting Lymph Node Metastasis in Early Gastric Cancer Patients状态不明NCT03632746牵头方(推断)2018-09 启动
  38. Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer状态不明NCT03480256牵头方(推断)I期2018-07 启动
  39. Laparoscopic Versus Open Gastrectomy for Elderly Local Advanced Gastric Cancer Patients状态不明NCT03564834牵头方(推断)II期2018-08 启动
  40. Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer状态不明NCT03575637牵头方(推断)II期2018-07 启动
  41. Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy状态不明NCT04993378牵头方(推断)2018-11 启动
  42. The Origin of Infrapyloric Artery已完成NCT03071237牵头方(推断)2017-03 启动
  43. MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer状态不明NCT03400657牵头方(推断)2017-11 启动
  44. Treatment Strategy for Stage IV Gastric Cancer with Positive Peritoneal Cytology As the Only Non-curable Factor已终止NCT02969122牵头方(推断)不分期2016-11 启动
  45. Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer状态不明NCT02610218牵头方(推断)2016-04 启动
  46. The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments状态不明NCT03493880牵头方(推断)2015-09 启动
  47. Octreotide LAR as Maintenance Treatment for Patients With NEC状态不明NCT02409849牵头方(推断)II期2015-04 启动
  48. A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy状态不明NCT02404753牵头方(推断)II期2015-04 启动
  49. Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer状态不明NCT02375997牵头方(推断)III期2014-10 启动
  50. Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer状态不明NCT02163291牵头方(推断)II期2013-12 启动
  51. Clinical Significance of Circulating Tumor Cells (CTCs) in Blood of Patients With Advanced/Metastatic Gastric Cancer已完成NCT01625702牵头方(推断)不分期2012-06 启动
  52. A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery状态不明NCT01679340牵头方(推断)II期2011-04 启动
  53. Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis状态不明NCT01471132牵头方(推断)II期2011-09 启动
  54. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  55. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  56. A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment正在招募NCT07518147研究中心III期2026-05 启动
  57. A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07315750研究中心III期2026-01 启动
  58. A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)正在招募NCT07221149研究中心II/III期2026-03 启动
  59. A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors正在招募NCT07354711研究中心I/II期2026-01 启动
  60. LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma正在招募NCT07362186研究中心III期2026-04 启动
  61. Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer正在招募NCT07522151研究中心III期2026-05 启动
  62. Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma正在招募NCT07700979研究中心III期2026-09 启动
  63. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer正在招募NCT06731478研究中心III期2025-02 启动
  64. SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors正在招募NCT06873659研究中心I期2025-02 启动
  65. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)正在招募NCT06760819研究中心II期2025-02 启动
  66. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors正在招募NCT07066657研究中心I期2025-07 启动
  67. A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma即将招募NCT06944496研究中心III期2025-05 启动
  68. To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors正在招募NCT07594964研究中心I期2025-08 启动
  69. An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors正在招募NCT07371663研究中心I/II期2025-12 启动
  70. A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma正在招募NCT07023315研究中心III期2025-08 启动
  71. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  72. BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.正在招募NCT06773312研究中心I期2025-02 启动
  73. A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway即将招募NCT06614751研究中心I期2024-11 启动
  74. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  75. A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)正在招募NCT07547787研究中心2024-12 启动
  76. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy正在招募NCT06221748研究中心II/III期2024-02 启动
  77. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)正在招募NCT06469944研究中心I/II期2024-09 启动
  78. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT06155383研究中心II期2023-11 启动
  79. M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.正在招募NCT06177041研究中心III期2023-12 启动
  80. AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy正在招募NCT06035250研究中心2023-09 启动
  81. Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics正在招募NCT05722275研究中心2023-01 启动
  82. A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors正在招募NCT06008054研究中心II期2023-11 启动
  83. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor正在招募NCT05262491研究中心I期2022-02 启动
  84. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  85. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors正在招募NCT05208762研究中心I期2022-10 启动
  86. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors正在招募NCT04900818研究中心I期2021-06 启动
  87. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)进行中,不再招募NCT06710132研究中心I/II期2025-01 启动
  88. A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification已终止NCT06585488研究中心I期2024-12 启动
  89. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.进行中,不再招募NCT06116136研究中心I/II期2024-08 启动
  90. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors进行中,不再招募NCT06257264研究中心I期2024-03 启动
  91. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China已完成NCT06585501研究中心2024-08 启动
  92. A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer进行中,不再招募NCT05980481研究中心II/III期2023-08 启动
  93. ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.进行中,不再招募NCT05632939研究中心I/II期2023-02 启动
  94. Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer状态不明NCT06008925研究中心I/II期2022-11 启动
  95. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  96. To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors已完成NCT05253053研究中心I/II期2022-04 启动
  97. Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1已完成NCT05383482研究中心I/II期2022-07 启动
  98. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer已终止NCT05149807研究中心II/III期2022-01 启动
  99. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  100. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs已完成NCT04852679研究中心III期2021-05 启动
  101. A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer进行中,不再招募NCT04950322研究中心III期2021-12 启动
  102. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  103. A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction已完成NCT04661150研究中心II期2021-03 启动
  104. A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)已终止NCT04933227研究中心II期2021-08 启动
  105. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)进行中,不再招募NCT04704934研究中心III期2021-05 启动
  106. Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer进行中,不再招募NCT04725994研究中心I/II期2021-06 启动
  107. Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor状态不明NCT05009966研究中心I期2021-09 启动
  108. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  109. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations状态不明NCT05019794研究中心II期2020-05 启动
  110. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  111. Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab已完成NCT04276493研究中心I/II期2020-03 启动
  112. Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis状态不明NCT04222114研究中心III期2020-10 启动
  113. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors已完成NCT04400383研究中心I期2020-06 启动
  114. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  115. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  116. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment已终止NCT04178460研究中心I期2020-02 启动
  117. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  118. A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma已完成NCT03852251研究中心I/II期2019-01 启动
  119. A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy已完成NCT03813784研究中心III期2019-03 启动
  120. A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer状态不明NCT04139135研究中心III期2019-12 启动
  121. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  122. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer已完成NCT04082364研究中心II/III期2019-09 启动
  123. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers状态不明NCT03468712研究中心不分期2018-03 启动
  124. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  125. A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer已完成NCT03472365研究中心II期2018-04 启动
  126. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2已完成NCT03556345研究中心II期2018-07 启动
  127. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)已完成NCT03615326研究中心III期2018-10 启动
  128. A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor状态不明NCT03393416研究中心I期2018-04 启动
  129. Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer已完成NCT03427814研究中心II期2018-07 启动
  130. Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors状态不明NCT03507998研究中心I期2017-06 启动
  131. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer状态不明NCT03273920研究中心不分期2017-09 启动
  132. Incidence of Pancreatic Fistula After Radical Gastrectomy状态不明NCT03391687研究中心2017-12 启动
  133. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer已完成NCT02898077研究中心III期2017-03 启动
  134. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)已终止NCT03019588研究中心III期2017-02 启动
  135. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)已完成NCT03221426研究中心III期2017-10 启动
  136. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer状态不明NCT02845986研究中心II期2016-09 启动
  137. Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis状态不明NCT03023436研究中心III期2016-01 启动
  138. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  139. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  140. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery状态不明NCT02130752研究中心不分期2014-10 启动
  141. Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer状态不明NCT02378389研究中心I期2014-09 启动
  142. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动
  143. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer已完成NCT01774786研究中心III期2013-06 启动
  144. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动
  145. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)状态不明NCT01609309研究中心III期2012-09 启动
  146. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer已终止NCT01641939研究中心II/III期2012-09 启动
  147. Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer已完成NCT00202969研究中心III期2005-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 1120232024: 1120242025: 002025

北京有 37 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科
牵头的论文4
  1. Knockdown of PRDX2 Inhibits the Proliferation, Growth, Migration, Invasion, and MMP9 Activity of Ewing's Sarcoma Cells Cultured In Vitro.2024Cancer reports (Hoboken, N.J.)
  2. Regulatory role of PI3K/Akt/WNK1 signal pathway in mouse model of bone cancer pain.2023Scientific reports
  3. SNHG9/miR-214-5p/SOX4 feedback loop regulates osteosarcoma progression.2022Neoplasma
  4. Primary EWS/PNET of the lung with TP53 germline and SKT11 somatic mutation: A case report and review of the literature.2022Thoracic cancer
早期论文(2016–2020 年)6
  1. KIF18B promotes tumor progression in osteosarcoma by activating β-catenin.2020Cancer biology & medicine
  2. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.2020International journal of clinical oncology
  3. Construction of Anti-hPD-L1 HCAb Nb6 and in Situ 124I Labeling for Noninvasive Detection of PD-L1 Expression in Human Bone Sarcoma.2019Bioconjugate chemistry
  4. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.2019Molecular carcinogenesis
  5. Association between interleukin 8 -251 A/T and +781 C/T polymorphisms and osteosarcoma risk in Chinese population: a case-control study.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  6. [Deficiencies in the Diagnosis and Treatment of Pulmonary Metastatic Osteosarcoma: A Chinese Multidisciplinary Survey].2016Zhongguo fei ai za zhi = Chinese journal of lung cancer
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors已终止NCT06438783研究中心I期2024-02 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 12 篇,占 2.3%。

牵头论文
12
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 4420232024: 5520242025: 112025

北京有 19 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
    分期
    II期
    开始
    2025-07
    登记号
    NCT07559864

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院北京

  2. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科肿瘤内科普外/肝胆胰外科
牵头的论文12
  1. Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial.2025CancerRCT
  2. Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies.2024Clinical cancer research : an official journal of the American Association for Cancer Research
  3. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.2024European journal of cancer (Oxford, England : 1990)RCT
  4. CT features combined with RECIST 1.1 criteria improve progression assessments of sunitinib-treated gastrointestinal stromal tumors.2024European radiology
  5. Percutaneous ultrasound-guided radiofrequency ablation for patients with liver metastases from gastrointestinal stromal tumors.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  6. An additional gastrojejunostomy may reduce the incidence of moderate and severe delayed gastric emptying after distal segmental duodenectomy for gastrointestinal stromal tumors.2024World journal of surgical oncology
  7. Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.2023Advances in therapy
  8. Cytoreductive surgery offers prognostic benefits in metastatic gastrointestinal stromal tumors with generalized progression following imatinib therapy: a single institute retrospective study.2023BMC surgery
  9. Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study.2023The oncologist
  10. Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.2023The oncologist
  11. Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study.2022Clinical cancer research : an official journal of the American Association for Cancer Research
  12. Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?2021European journal of radiology
早期论文(2016–2020 年)16
  1. The current status of and prospects in research regarding gastrointestinal stromal tumors in China.2020Cancer
  2. A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.2020Cancer medicine
  3. Heterogeneity of metastatic gastrointestinal stromal tumor on texture analysis: DWI texture as potential biomarker of overall survival.2020European journal of radiology
  4. [Current status and progress in novel drug research for gastrointestinal stromal tumors].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. Cytoreductive surgery for metastatic gastrointestinal stromal tumors followed by sunitinib compared to followed by imatinib-a multi-center cohort study.2019European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  6. [Advances in radiological studies of gastrointestinal stromal tumors].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [To improve the understanding of CD117-negative gastrointestinal stromal tumor].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. MRI in predicting the response of gastrointestinal stromal tumor to targeted therapy: a patient-based multi-parameter study.2018BMC cancer
  9. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.2018Future oncology (London, England)
  10. Non-Gaussian diffusion imaging with a fractional order calculus model to predict response of gastrointestinal stromal tumor to second-line sunitinib therapy.2018Magnetic resonance in medicine
  11. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.2018World journal of gastroenterology
  12. [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].2018Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  13. Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes.2017Future oncology (London, England)
  14. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.2016Oncotarget
  15. [Molecular mechanism of gastrointestinal stromal tumors and progress in drug research].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  16. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)15
  1. A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST状态不明NCT02776878牵头方不分期2016-05 启动
  2. Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment正在招募NCT07559864牵头方(推断)II期2025-07 启动
  3. A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment即将招募NCT06772233牵头方(推断)II期2025-07 启动
  4. Ripretinib in Chinese Patients With Advanced GIST: a Real World Study状态不明NCT05697107牵头方(推断)2021-05 启动
  5. Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics状态不明NCT04584008牵头方(推断)不分期2020-09 启动
  6. Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial状态不明NCT04106024牵头方(推断)II期2018-10 启动
  7. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动
  8. Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World已完成NCT05381753研究中心2022-08 启动
  9. A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)进行中,不再招募NCT05245968研究中心I期2021-12 启动
  10. Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients已完成NCT05400018研究中心2020-11 启动
  11. A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)已完成NCT04282980研究中心II期2020-04 启动
  12. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib已完成NCT04633122研究中心II期2020-11 启动
  13. A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor已完成NCT04254939研究中心I/II期2019-08 启动
  14. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST已完成NCT03465722研究中心III期2018-03 启动
  15. Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor已完成NCT00793871研究中心IV期2008-11 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

北京有 23 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

北京有 16 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.2%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

北京有 14 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录
研究主题干细胞移植

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年没有牵头抗 NMDA 受体脑炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 13 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

北京大学肿瘤医院

Peking University Cancer Hospital

北京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Peking University Cancer Hospital & Institute; Peking University Cancer Hospital and Institute; Beijing Cancer Hospital and Institute; Beijing Cancer Hospital; Peking University Cancer Hospital Yunnan; Beijing Cancer Hospital & Institute; Peking University Cancer Hospital/Institute; Peking University Cancer Hospital &Institute

提出更正下载数据